Citius Pharmaceuticals Inc (NASDAQ:CTXR) shares were up 13.7% on Friday . The company traded as high as $0.60 and last traded at $0.58, approximately 349,927 shares traded hands during trading. An increase of 127% from the average daily volume of 154,089 shares. The stock had previously closed at $0.51.
A number of equities research analysts have recently weighed in on CTXR shares. ValuEngine raised Citius Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Zacks Investment Research raised Citius Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 22nd. Finally, Dawson James started coverage on Citius Pharmaceuticals in a report on Friday, September 6th. They set a “buy” rating and a $7.00 target price for the company.
The firm has a market cap of $12.72 million, a price-to-earnings ratio of -0.49 and a beta of 0.49. The stock has a 50 day moving average of $0.50 and a 200 day moving average of $0.87.
A hedge fund recently raised its stake in Citius Pharmaceuticals stock. Vanguard Group Inc. boosted its stake in Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 453,156 shares of the company’s stock after purchasing an additional 342,180 shares during the quarter. Vanguard Group Inc. owned about 2.05% of Citius Pharmaceuticals worth $444,000 at the end of the most recent reporting period. 16.59% of the stock is owned by hedge funds and other institutional investors.
About Citius Pharmaceuticals (NASDAQ:CTXR)
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
See Also: What is a Lock-Up Period?
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.